Global Emerging Innovation Summit (GEIS-2021)

Myxobacterial Metabolites: A Promising Resource for Big Pharma

Author(s): Akshay Mohan, Daljeet Singh Dhanjal, Chirag Chopra and Reena Singh * .

Pp: 360-365 (6)

DOI: 10.2174/9781681089010121010044


Abstract: The lives of people have been better since the discovery of medicines. Experts were able to discover a cure for even a few chronic diseases like cancer. Scientific studies from multiple areas, including biology, chemistry, and biotechnology, have created a diverse array of solutions to the issues faced by humans in health and medicine. The usage of microorganisms to make valuable products that are important to treat various diseases and improve people's lives by using it in many industrial levels like food, pharmaceutical, and agricultural sectors has made microbial species that include bacteria and fungus, etc., ever-demanding. Research studies from the past few decades proved that many bacteria, including myxobacteria, have been used as a potent source for deriving lots of compounds that could be useful for humans like antibacterial, antifungal, anticancer agents, and enzymes that can degrade cellulose, protein, etc. Since it's a proteobacterium commonly found in organic dwells and swamps, it would be feasible to cultivate this bacterial species to produce chemical compounds with more incredible industrial applications. This review will explain why myxobacterium is considered a potential source for the production of industrially important enzymes and many other beneficial secondary metabolites. Also, this review will shed light on various ways to screen and characterize the myxobacterial population to produce cellulolytic enzymes.

Keywords: Cellulase, Enzyme, Myxobacteria, Proteobacteria, Secondary Metabolites.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy